Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD5 | P21918 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 12/20 | 0.40 |
| ▸ | AKT1 | P31749 | 6/20 | 0.40 |
| ▸ | AKT2 | P31751 | 2/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22166063 | 0.81 | DRD2 (0.43) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL25317065 | 0.73 | PTGS1 (0.41) | RPS6KB1AKT1AKT2AKT3KCNH2 | |
| SCHEMBL22165991 | 0.71 | CA1 (0.39) | DRD2DRD1DRD4DRD5DRD3 | |
| Hydrochloric Acid SCHEMBL15732655 | 0.69 | HTR2C (0.50) | RPS6KB1AKT1 | |
| SCHEMBL22444698 | 0.69 | DRD2 (0.57) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL440139 | 0.68 | TDP1 (0.49) | — | |
| SCHEMBL407247 | 0.68 | TDP1 (0.49) | — | |
| SCHEMBL1713465 | 0.68 | KIF11 (0.55) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL18552902 | 0.68 | DRD2 (0.39) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL21590356 | 0.67 | DRD3 (0.62) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747244-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2025-04-17 | — | — | US | disclosed |
| WO-2025017305-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025017306-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| EP-4466071-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | Redx Pharma Limited (GB) | 2024-11-27 | — | — | EP | disclosed |
| CN-118632845-A | Modulators of Rho-associated protein kinase (ROCK) | 莱德克斯制药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | DRD2 4467/4885DRD1 4544/4885DRD4 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.